New gene therapy treatment routes for motor neurone disease uncovered in new study

July 14, 2017
New gene therapy treatment routes for motor neurone disease uncovered in new study
Credit: University of Sheffield

Scientists investigating the genetic causes and altered functioning of nerve cells in motor neurone disease (MND) have discovered a new mechanism that could lead to fresh treatment approaches for one of the most common forms of the disease.

The team, based in the Sheffield Institute for Translational Neuroscience (SITraN), investigated a mutation in one particular gene, which causes sections of DNA to replicate themselves inexplicably within . They found a way to prevent RNA, carrying these replicated sequences, from leaving the cell's nucleus and travelling into the surrounding cytoplasm where they cause cell death.

Patients with MND suffer progressive paralysis as the nerves supplying muscles degenerate. Although there are several different types of MND, this mutation, in a gene called C9ORF72, is responsible for the most common type of MND, called Amyotrophic Lateral Sclerosis (ALS). This accounts for about 40-50 per cent of inherited cases and 10 per cent of all MND cases. The mutations or environmental factors causing the vast majority of MND cases remain unknown.

DNA is produced in the cell's nucleus and contains the instructions which cells use to carry out their functions. Messenger RNA, called mRNA, transcribes this information and carries it out of the cell to 'protein factories' in the cytoplasm surrounding the nucleus. It is quite common for some sections of repeated DNA stretches to replicate themselves for reasons that are poorly understood. These repetitions are 'non-coding' sections that are not responsible for building proteins and are edited out before they leave the nucleus to serve as templates for the production of proteins.

In this particular type of motor neurone disease, however, the RNA not only contains the unnecessary replicated sequences, it is able to take them out of nucleus and into the cell's cytoplasm. Once in the cytoplasm, the RNA is used to make up repeated proteins that clump together and block the normal function of the cell, causing it to die.

In an early stage study, published in Nature Communications, the researchers have been able to pinpoint why the repeated RNA sequences are able to leave the cell's nucleus to cause cell death. The team identified a particular protein called SRSF1 which binds to the pathological repeated RNA molecules and transports them out of the cell centre, effectively overriding the gatekeeping machinery within the nucleus by opening a back door.

Working in partnership with researchers at the MRC Mitochondrial Biology Unit at the University of Cambridge, the team have shown that by targeting the SRSF1 protein, it is possible to reduce the amount of rogue RNA escaping into the cell's cytoplasm.

"This is a completely new approach to tackling the most common type of motor neurone disease. No one has yet attempted to prevent these repeated sequences of RNA from leaving the cell's nucleus and it opens up new areas of investigation for gene therapy," explains University of Sheffield's Dr Guillaume Hautbergue, who conceived the study and led the research jointly with Dr Alexander Whitworth, of the University of Cambridge, and SITraN Director, Professor Dame Pamela Shaw.

The team have been investigating ways to reduce the levels of SRSF1 in the cell, or to alter its makeup so that it is unable to interact with the cell's export machinery, reducing the amount of rogue RNA molecules to escape into the cell's cytoplasm. Instead, the RNA builds up in the nucleus, but eventually degrades as no adverse effects were observed within the nerve cells.

These methods have been successfully tested in the laboratory in reprogrammed from patient's skins and in a fruitfly model of disease. New in vivo tests in mice, the closest model to human disease, are planned to start later this year.

"Repeated RNA transcripts are also present in other neurodegenerative diseases, including Huntington's Disease, Myotonic Dystrophy, Spinocerebellar Ataxias and Fragile X-associated Temor/Ataxia syndrome," added Dr Hautbergue. "Although we are at a very early stage in our research, it's possible that our approach could open up new possibilities for gene therapies for these diseases as well once we have investigated how the RNA molecules carrying the -specific replicated sequences leave the cell's to travel into the surrounding cytoplasm."

The research is funded by the Motor Neurone Disease Association and the Medical Research Council, and a patent covering the potential therapeutic treatment of neurodegenerative diseases by targeting SRSF1 has also been filed.

Explore further: New study reveals how RNA splicing errors may spark the development of both ALS and a form of dementia

Related Stories

New study reveals how RNA splicing errors may spark the development of both ALS and a form of dementia

June 13, 2017
The most frequent genetic cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD)—rare and related neurological disorders marked by progressive deterioration of motor or cognitive abilities—may ...

New areas of the brain identified where ALS-implicated gene is active

August 1, 2016
For the first time novel expression sites in the brain have been identified for a gene which is associated with motor neuron disease and frontotemporal dementia.

Motor neuron disease discovery offers new insights into potential treatment targets

May 30, 2017
Scientists have discovered how certain forms of motor neuron disease begin and progress at cellular and molecular levels, revealing potential new ways to slow down or even stop this process. The team are already working closely ...

New research into delaying the onset of motor neurone disease shows positive results

May 25, 2017
New research conducted by scientists at the University of Sheffield into a drug candidate which could help to delay the onset of motor neurone disease has shown encouraging early results.

'Detective' iSHiRLoC investigates role of RNA, could help researchers study genesis of cancer

April 19, 2017
A team of University of Michigan scientists have developed a tool to help them study dysfunction in cells by tracking a molecule called microRNA, possibly giving them a way to determine how cancer occurs and spreads in the ...

Recommended for you

Gene immunotherapy protects against multiple sclerosis in mice

September 21, 2017
A potent and long-lasting gene immunotherapy approach prevents and reverses symptoms of multiple sclerosis in mice, according to a study published September 21st in the journal Molecular Therapy. Multiple sclerosis is an ...

Neuron types in brain are defined by gene activity shaping their communication patterns

September 21, 2017
In a major step forward in research, scientists at Cold Spring Harbor Laboratory (CSHL) today publish in Cell a discovery about the molecular-genetic basis of neuronal cell types. Neurons are the basic building blocks that ...

Highly precise wiring in the cerebral cortex

September 21, 2017
Our brains house extremely complex neuronal circuits whose detailed structures are still largely unknown. This is especially true for the cerebral cortex of mammals, where, among other things, vision, thoughts or spatial ...

Your neurons register familiar faces, whether you notice them or not

September 21, 2017
When people see an image of a person they recognize—the famous tennis player Roger Federer or actress Halle Berry, for instance—particular cells light up in the brain. Now, researchers reporting in Current Biology on ...

Faulty cell signaling derails cerebral cortex development, could it lead to autism?

September 20, 2017
As the embryonic brain develops, an incredibly complex cascade of cellular events occur, starting with progenitors - the originating cells that generate neurons and spur proper cortex development. If this cascade malfunctions ...

Strategy might prevent infections in patients with spinal cord injuries

September 19, 2017
New research led by The Ohio State University Wexner Medical Center found a potential therapeutic strategy to prevent infections in patients with spinal cord injuries.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.